Figure 6: Med23 deficiency enhances the antitumour function of T cells.
From: The mediator subunit Med23 contributes to controlling T-cell activation and prevents autoimmunity
(a) Tumour onset was monitored for PyMT WT and PyMT Med23−/− mice (PyMT WT, n=28; PyMT Med23−/−, n=27; P<0.0001 by log-rank test). (b) Haematoxylin and eosin-stained mammary tumour sections of PyMT WT and PyMT Med23−/− mice (magnification, × 40 and × 400; scale bars, 200 μm) (c) Tumour growth in PyMT WT and PyMT Med23−/− mice. Mammary tumour volumes were measured with calipers starting from 6 weeks after birth and continuing until 20 weeks of age (PyMT WT, n=20; PyMT Med23−/−, n=16; *P<0.05, **P<0.01 and ***P<0.001 by Student’s t-test). (d) Flow cytometry analysis of CD44 expression in tumour-infiltrating T cells. The production of IL-2 (e), IFNγ (f) and TNFα (g) from tumour-infiltrating T cells was analysed by flow cytometry. Granzyme B (h) and perforin (i) expression in tumour-infiltrating CD8+ T cells was assessed. Error bars indicate s.e.m. All results are representative of or combined from at least three independent experiments.
